\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
(Adds CDC decision)
By Mrinalika Roy
July 19 (Reuters) – The U. S. Centers for Disease Control and Prevention (CDC)The U. S. Government approved the use of Novavax Inc. ‘s COVID-19 vaccine on Tuesday. for others over the age of 18.
CDC Director Rochelle Walensky said the resolution “expanded the availability” for vaccines from U. S. adults.
“If you expected a COVID-19 vaccine based on a different generation than what was available in the past, now is the time to sign up for the millions of Americans who have been vaccinated,” he said.
The recommendation came after the CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously subsidized the vaccine, a week after the U. S. Food and Drug Administration had unanimously subsidized the vaccine. The U. S. Department of Homeland Security will legalize the vaccine as a two-dose vaccination series number one.
The U. S. government The U. S. has received 3. 2 million doses of the Novavax vaccine. Novavax said in an email that it plans to send doses for the U. S. government to sendThe U. S. Department of Homeland Security will distribute them in the coming days.
More than 77% of U. S. adults have been vaccinated with injections from Moderna Inc, Pfizer-BioNTech or Johnson
Novavax hopes its protein-based vaccine may be more widely accepted among vaccine skeptics, as it uses an older generation than messenger RNA vaccines. Protein-based vaccines have been used for decades to fight diseases such as hepatitis B and influenza.
With Novavax’s vaccines, “we want to focus on this population in the hope that (the new vaccine) will save them from going unvaccinated,” said Dr. Oliver Brooks, one of ACIP’s voting members.
In a clinical trial of 30,000 participants conducted before the advent of the unvaccinated Omicron variant, the two-dose vaccine is about 90% effective in preventing COVID disease.
In July, Novavax said the vaccine exhibited a broad immune reaction to the recently circulating variants, subvariants of Omicron BA. 4/5.
The Serum Institute of India, the company’s production partner, last week obtained FDA approval to export the vaccine to the country.
The Novavax vaccine has been available in Europe since December, but there has been no significant demand there. More than thirteen million doses of vaccine have been distributed in the EU, but only about 250,000 doses of vaccine have been administered.
Last week, the European Medicines Agency reported severe allergic reactions as possible side effects of the vaccine, while the product’s U. S. label reported severe allergic reactions as possible side effects of the vaccine. The U. S. Food and Drug Administration warns against administering the vaccine to others with a history of allergic reactions to any of the components of the vaccine.
Novavax has tested an updated vaccine based on the first variant BA. 1 Omicron and expects it to be available until the fourth trimester.
The company has also accelerated the progression of vaccines as opposed to subvariants BA. 4 and BA. 5 and expects to get more preclinical information about this in the summer or fall. (Reports by Mrinalika Roy in Bengaluru; additional reports by Michael Erman in York; Edited by David Gregorio and Richard Pullin)